Natural Compound

CoQ10

Ubiquinone-10 (2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone)

Evidence TierAWADA NOT PROHIBITED

tuneTypical Dose

100-300 mg per day

watchEffect Window

4-12 weeks for symptomatic changes. Up to 2 years for mortality outcomes in heart failure.

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Coenzyme Q10 is a fat-soluble mitochondrial cofactor needed for electron transport and antioxidant defense. It is used for heart function support, migraine prevention, and statin-associated symptom mitigation.

Clinical evidence supports symptom and functional improvements in heart failure and modest reductions in migraine frequency. A 2025 meta-analysis also supports a real but modest reduction in statin-associated muscle pain, which makes CoQ10 most relevant for people who want to stay on statin therapy but are limited by SAMS. Minority benefits include small blood pressure reductions and improved male fertility markers.

Essential coenzyme in the mitochondrial electron transport chain (Complex I to III shuttle). Facilitates ATP production in high-energy tissues (heart, brain, muscle). Also functions as a potent lipid-soluble antioxidant protecting membranes and LDL from oxidation.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Reduces cardiovascular mortality and hospitalization in chronic heart failure (Q-SYMBIO trial)
  • Repletes statin-depleted CoQ10 levels with mixed-to-positive relief of statin-associated myopathy

Secondary Outcomes

  • Modest blood pressure reduction
  • General mitochondrial energy support in aging

Safety

Contraindications and Interactions

Contraindications

  • Warfarin or other vitamin K antagonist therapy without INR monitoring
  • Pregnancy (caution)
  • Lactation (caution)

Side effects

  • Mild GI upset (nausea, vomiting, abdominal pain, diarrhea, constipation, more common at higher doses)
  • Headache
  • Reduced blood pressure
  • Insomnia if taken late
  • Decreased appetite
  • Heartburn

Interactions

  • Warfarin or vitamin K antagonists (Possible/Moderate) - May reduce INR and anticoagulant effectiveness. Monitor INR closely.
  • Blood-pressure-lowering drugs (Probable/Moderate) - Additive blood pressure lowering. Monitor for dizziness or hypotension.
  • Fish oil (Possible/Minor) - Co-administration with EPA/DHA may lower achieved CoQ10 levels.
  • Red yeast rice (Theoretical/Minor) - May further deplete endogenous CoQ10 via the HMG-CoA reductase pathway.
  • Amitriptyline (Theoretical/Unknown) - May lower CoQ10 levels.
  • P-glycoprotein substrates (Theoretical/Unknown) - CoQ10 may alter substrate exposure.
  • Theophylline (Theoretical/Unknown) - CoQ10 may increase theophylline exposure.
  • Chemotherapy agents (Theoretical/Moderate) - Antioxidant use may interfere with ROS-dependent regimens. Coordinate with oncology.
  • Insulin or oral hypoglycemics (Possible/Minor) - May modestly enhance glucose lowering.
  • Vitamin K pathway (Theoretical/Unknown) - In vitro inhibition of vitamin-K-dependent carboxylase. Reinforces anticoagulant monitoring.

Avoid if

  • On warfarin or other vitamin K antagonists without INR monitoring
  • Active chemotherapy without oncologist approval
  • Pregnancy considerations
  • Lactation considerations
  • Symptomatic hypotension while using blood-pressure-lowering drugs

Evidence

Study-level References

coq10-SRC-001RCT (Multicenter)
Sourceopen_in_new

Mortensen SA, et al. "The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial." JACC Heart Fail. 2014.

Population: Patients with moderate-to-severe heart failure

Dose protocol: Source-listed

Key findings: Long-term CoQ10 treatment of patients with chronic HF is safe, improves symptoms, and reduces major adverse cardiovascular events.

Notes: Source mapping to primary literature is incomplete in this dataset. Apply conservative interpretation and validation checks.

Paper content

Long-term CoQ10 treatment of patients with chronic HF is safe, improves symptoms, and reduces major adverse cardiovascular events.

coq10-SRC-002Systematic review and meta-analysis of randomized controlled trials
Sourceopen_in_new

Kovacic S, et al. Effects of coenzyme Q10 supplementation on myopathy in statin-treated patients. A systematic review and meta-analysis. J Nutr Sci. 2025;14:e72. doi:10.1017/jns.2025.10043. PMID:41158831.

Population: Adults taking statins with statin-associated muscle symptoms

Dose protocol: 100-600 mg/day for 30-90 days across 7 RCTs in statin-treated adults.

Key findings: Meta-analysis found a modest but significant reduction in statin-associated muscle pain intensity versus control.

Notes: Useful for SAMS mitigation, but it does not guarantee symptom resolution in every statin-treated patient.

Paper content

Meta-analysis of 7 RCTs found a modest but statistically significant reduction in statin-associated muscle pain with CoQ10. Individual trials were mixed, so the signal is useful but not definitive.

Guides

Setup

Help